Scientific work

Prof. Dr. Saadettin Kılıçkap

479 publications. The source of the information is stated next to each publication.

Back to profile
  1. Determining the Current Situation of Geriatric Oncology in Turkey: A Survey of Medical Oncologists

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2020-80824 Open-access full textSource: OpenAlex

  2. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.11.013 PMID 34861371 133 citations (Europe PMC) Open-access full textSource: OpenAlex

  3. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department

    Cureus, 2021

    DOI 10.7759/cureus.17880 PMID 34660079 Open-access full textSource: OpenAlex

  4. Thirty-day mortality rates after immunotherapy initiation

    Immunotherapy, 2021

    DOI 10.2217/imt-2021-0082 PMID 34676791 2 citations (Europe PMC) Source: Europe PMC

  5. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

    International Journal of Clinical Oncology, 2021

    DOI 10.1007/s10147-021-01936-6 PMID 34023933 14 citations (Europe PMC) Source: ORCID

  6. Merkel cell carcinoma in Turkey: A multicentric study

    Journal of Cancer Research and Therapeutics, 2021

    DOI 10.4103/jcrt.jcrt_950_19 PMID 34916389 3 citations (Europe PMC) Open-access full textSource: ORCID

  7. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors

    Biomarkers in medicine, 2021

    DOI 10.2217/bmm-2020-0674 PMID 34397271 8 citations (Europe PMC) Source: Europe PMC

  8. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

    Frontiers in Oncology, 2021

    DOI 10.3389/fonc.2021.759108 PMID 34804957 25 citations (Europe PMC) Open-access full textSource: ORCID

  9. Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist’s impact on anticoagulant therapy

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05669-6 PMID 32776163 9 citations (Europe PMC) Source: ORCID

  10. Blood based biomarkers as predictive factors for hyperprogression

    Research Square, 2021

    DOI 10.21203/rs.3.rs-991928/v1 Open-access full textSource: ORCID

  11. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220965677 PMID 33070764 7 citations (Europe PMC) Source: ORCID

  12. Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data

    International Journal of Cancer, 2021

    DOI 10.1002/ijc.33426 PMID 33284987 16 citations (Europe PMC) Open-access full textSource: ORCID

  13. Comparison of respiratory muscle strength and endurance, maximal oxygen consumption, and fatigue in colorectal cancer survivors with healthy adults

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05963-3 PMID 33392768 3 citations (Europe PMC) Source: ORCID

  14. Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study

    Journal of B.U.ON., 2021

    Source: ORCID

  15. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: Which is better?

    Journal of B.U.ON., 2021

    PMID 34761618 2 citations (OpenAlex) Source: ORCID

  16. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05702-8 PMID 32851486 10 citations (Europe PMC) Source: ORCID

  17. PILE: a candidate prognostic score in cancer patients treated with immunotherapy

    Clinical and Translational Oncology, 2021

    DOI 10.1007/s12094-021-02560-6 PMID 33586122 24 citations (Europe PMC) Source: ORCID

  18. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-021-06139-3 PMID 33709186 20 citations (Europe PMC) Source: ORCID

  19. Same disease, different approaches: A report on six lymphoma cases with extranodal marginal zones in rare sites

    Journal of Oncological Science, 2021

    DOI 10.37047/jos.2020-79452 1 citation (OpenAlex) Open-access full textSource: ORCID

  20. The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study

    Research Square, 2021

    DOI 10.21203/rs.3.rs-747492/v1 Open-access full textSource: ORCID

  21. The Relationship Between Systemic Immune Inflammation Index and Treatment Response in Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors: Results from The Turkish Oncology Group Kidney Cancer Consortium Database

    Research Square, 2021

    DOI 10.21203/rs.3.rs-1101225/v1 Open-access full textSource: ORCID

  22. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

    Current Problems in Cancer, 2021

    DOI 10.1016/j.currproblcancer.2021.100760 PMID 34130864 16 citations (Europe PMC) Source: ORCID

  23. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0681 PMID 34409854 13 citations (Europe PMC) Source: ORCID

  24. The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients

    Medical Oncology, 2021

    DOI 10.1007/s12032-021-01512-y PMID 33891205 3 citations (Europe PMC) Open-access full textSource: ORCID

  25. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

    Journal of B.U.ON., 2021

    Source: ORCID

  26. What’s the difference between hyperprogressive disease and progressive disease for patients with treated immune checkpoint inhibitors?

    Research Square, 2021

    DOI 10.21203/rs.3.rs-1184111/v1 Open-access full textSource: ORCID

  27. 456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.977 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  28. 976P The 30-day mortality rate after first cycle of immunotherapy

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1360 Open-access full textSource: OpenAlex

  29. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

    BMJ Supportive & Palliative Care, 2021

    DOI 10.1136/bmjspcare-2021-003301 PMID 34711656 43 citations (OpenAlex) Source: OpenAlex

  30. MO368THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

    Nephrology Dialysis Transplantation, 2021

    DOI 10.1093/ndt/gfab082.0022 1 citation (OpenAlex) Source: OpenAlex

  31. OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.01.272 4 citations (OpenAlex) Open-access full textSource: OpenAlex

  32. FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.08.217 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  33. Physiological Cost in Daily Life Activities in Lung Cancer

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa762 Source: OpenAlex

  34. A comparison of respiratory muscle endurance, respiratory muscle endurance workload, and quality of life in low and high-fatigue colorectal cancer survivors

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa1992 Source: OpenAlex

  35. 85P The association between diabetes and survival in patients treated with immunotherapy

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.10.103 Open-access full textSource: OpenAlex

  36. 38P The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.10.054 Open-access full textSource: OpenAlex

  37. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

    Tumori Journal, 2020

    DOI 10.1177/0300891620969823 PMID 33167790 4 citations (Europe PMC) Source: OpenAlex

  38. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

    Lung Cancer, 2020

    DOI 10.1016/j.lungcan.2020.07.022 PMID 32799090 30 citations (Europe PMC) Source: OpenAlex

  39. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900908 PMID 32054412 9 citations (Europe PMC) Source: OpenAlex

  40. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.

    PubMed, 2020

    PMID 33099930 5 citations (Europe PMC) Source: OpenAlex

  41. Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-75080 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  42. Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer

    2020

    Source: OpenAlex

  43. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

    Bursa Uludag University - AVESIS, 2020

    Source: OpenAlex

  44. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience

    The Turkish Journal of Gastroenterology, 2020

    DOI 10.5152/tjg.2020.18919 PMID 32141816 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  45. Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients

    La radiologia medica, 2020

    DOI 10.1007/s11547-020-01240-9 PMID 32594427 31 citations (Europe PMC) Source: OpenAlex

  46. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences

    European Urology Focus, 2020

    DOI 10.1016/j.euf.2020.09.010 PMID 33008789 8 citations (Europe PMC) Source: ORCID

  47. Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer

    Annals of Nuclear Medicine, 2020

    DOI 10.1007/s12149-020-01494-3 PMID 32602032 21 citations (Europe PMC) Source: ORCID

  48. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219858657 PMID 31256744 3 citations (Europe PMC) Source: ORCID

  49. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219877234 PMID 31566114 10 citations (Europe PMC) Source: ORCID

  50. Docetaxel, cisplatin, and fluorouracil combination chemotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A retrospective study

    Journal of Oncological Science, 2020

    DOI 10.37047/jos.2020-76836 1 citation (OpenAlex) Open-access full textSource: ORCID